US20210347776A1 - Process for preparation of grapiprant - Google Patents
Process for preparation of grapiprant Download PDFInfo
- Publication number
- US20210347776A1 US20210347776A1 US17/383,978 US202117383978A US2021347776A1 US 20210347776 A1 US20210347776 A1 US 20210347776A1 US 202117383978 A US202117383978 A US 202117383978A US 2021347776 A1 US2021347776 A1 US 2021347776A1
- Authority
- US
- United States
- Prior art keywords
- formula
- compound
- grapiprant
- process according
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HZVLFTCYCLXTGV-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=C(C)N=C(C)C=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 HZVLFTCYCLXTGV-UHFFFAOYSA-N 0.000 title claims abstract description 104
- 229950004517 grapiprant Drugs 0.000 title claims abstract description 101
- 238000000034 method Methods 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 150000001875 compounds Chemical class 0.000 claims abstract description 124
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 72
- 238000006243 chemical reaction Methods 0.000 claims description 65
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 41
- 239000002904 solvent Substances 0.000 claims description 40
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 39
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 33
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 32
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 16
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 15
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 15
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 14
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims description 10
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical group [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 10
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 10
- 238000004821 distillation Methods 0.000 claims description 10
- DFWQXANLGSXMKF-UHFFFAOYSA-N ethyl n-(4-methylphenyl)sulfonylcarbamate Chemical compound CCOC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 DFWQXANLGSXMKF-UHFFFAOYSA-N 0.000 claims description 10
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 10
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 9
- 229960001760 dimethyl sulfoxide Drugs 0.000 claims description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 9
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 8
- 239000011701 zinc Substances 0.000 claims description 8
- 229910052725 zinc Inorganic materials 0.000 claims description 8
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 7
- 229940086542 triethylamine Drugs 0.000 claims description 7
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 6
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 239000012312 sodium hydride Substances 0.000 claims description 5
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 5
- 239000008096 xylene Substances 0.000 claims description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 4
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 4
- 239000011736 potassium bicarbonate Substances 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 4
- 235000019260 propionic acid Nutrition 0.000 claims description 4
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 claims description 4
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims description 4
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
- 150000001540 azides Chemical class 0.000 claims description 3
- 239000012973 diazabicyclooctane Substances 0.000 claims description 3
- 229940043279 diisopropylamine Drugs 0.000 claims description 3
- -1 lithium aluminum hydride Chemical compound 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- 239000003880 polar aprotic solvent Substances 0.000 claims description 3
- 235000011181 potassium carbonates Nutrition 0.000 claims description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 239000010409 thin film Substances 0.000 claims description 3
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 2
- 239000005695 Ammonium acetate Substances 0.000 claims description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 2
- 229940043376 ammonium acetate Drugs 0.000 claims description 2
- 235000019257 ammonium acetate Nutrition 0.000 claims description 2
- 235000019270 ammonium chloride Nutrition 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 238000005984 hydrogenation reaction Methods 0.000 claims description 2
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 2
- 239000000347 magnesium hydroxide Substances 0.000 claims description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- TZLVRPLSVNESQC-UHFFFAOYSA-N potassium azide Chemical compound [K+].[N-]=[N+]=[N-] TZLVRPLSVNESQC-UHFFFAOYSA-N 0.000 claims description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 claims description 2
- 229910000105 potassium hydride Inorganic materials 0.000 claims description 2
- 229910052703 rhodium Inorganic materials 0.000 claims description 2
- 239000010948 rhodium Substances 0.000 claims description 2
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims description 2
- 229910052707 ruthenium Inorganic materials 0.000 claims description 2
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims 1
- 229910052808 lithium carbonate Inorganic materials 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 abstract description 22
- 239000000543 intermediate Substances 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- 239000011541 reaction mixture Substances 0.000 description 40
- 239000000243 solution Substances 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- 239000010410 layer Substances 0.000 description 21
- 239000007962 solid dispersion Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 15
- 229920000642 polymer Polymers 0.000 description 14
- 239000007787 solid Substances 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 11
- 239000002245 particle Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- DNWQHWFJPGMXKH-UHFFFAOYSA-N CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCN)C=C1 Chemical compound CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCN)C=C1 DNWQHWFJPGMXKH-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000007868 Raney catalyst Substances 0.000 description 5
- 229910000564 Raney nickel Inorganic materials 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- HFTJOSWXQHUUKC-UHFFFAOYSA-N 1-[4-(2-azidoethyl)phenyl]-2-ethyl-4,6-dimethylimidazo[4,5-c]pyridine Chemical compound CCC1=NC2=C(C)N=C(C)C=C2N1C1=CC=C(CCN=[N+]=[N-])C=C1 HFTJOSWXQHUUKC-UHFFFAOYSA-N 0.000 description 4
- SCKCYPNUKGOGGS-UHFFFAOYSA-N CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCO)C=C1 Chemical compound CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCO)C=C1 SCKCYPNUKGOGGS-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- QXHDYMUPPXAMPQ-UHFFFAOYSA-N 2-(4-aminophenyl)ethanol Chemical compound NC1=CC=C(CCO)C=C1 QXHDYMUPPXAMPQ-UHFFFAOYSA-N 0.000 description 3
- ZEHYGSOQUDOOOW-UHFFFAOYSA-N CC1=CC(Cl)=C([N+](=O)[O-])C(C)=N1.NC1=CC=C(CCO)C=C1 Chemical compound CC1=CC(Cl)=C([N+](=O)[O-])C(C)=N1.NC1=CC=C(CCO)C=C1 ZEHYGSOQUDOOOW-UHFFFAOYSA-N 0.000 description 3
- DLUNNXZDDFQQIF-UHFFFAOYSA-N CC1=CC(NC2=CC=C(CCO)C=C2)=C(N)C(C)=N1 Chemical compound CC1=CC(NC2=CC=C(CCO)C=C2)=C(N)C(C)=N1 DLUNNXZDDFQQIF-UHFFFAOYSA-N 0.000 description 3
- BONUBWFXPMDPPC-UHFFFAOYSA-N CC1=CC(NC2=CC=C(CCO)C=C2)=C([N+](=O)[O-])C(C)=N1.Cl Chemical compound CC1=CC(NC2=CC=C(CCO)C=C2)=C([N+](=O)[O-])C(C)=N1.Cl BONUBWFXPMDPPC-UHFFFAOYSA-N 0.000 description 3
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- VLJQDHDVZJXNQL-UHFFFAOYSA-N 4-methyl-n-(oxomethylidene)benzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)N=C=O)C=C1 VLJQDHDVZJXNQL-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- QPAJMSMQHOVLGH-UHFFFAOYSA-O CCC1=NC2=C(C)[N+](O)=C(C)C=C2N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=CC=C(C)C=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=C(C)C=CC=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=CC(C)=CC=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNS(=O)(=O)C2=CC=C(C)C=C2)C=C1 Chemical compound CCC1=NC2=C(C)[N+](O)=C(C)C=C2N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=CC=C(C)C=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=C(C)C=CC=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=CC(C)=CC=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNS(=O)(=O)C2=CC=C(C)C=C2)C=C1 QPAJMSMQHOVLGH-UHFFFAOYSA-O 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- NCAPIWDYXGDHIK-UHFFFAOYSA-L [Li+].[K+].OC([O-])=O.OC([O-])=O Chemical compound [Li+].[K+].OC([O-])=O.OC([O-])=O NCAPIWDYXGDHIK-UHFFFAOYSA-L 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920000831 ionic polymer Polymers 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- BIIBYWQGRFWQKM-JVVROLKMSA-N (2S)-N-[4-(cyclopropylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-2-[[(E)-3-(2,4-dichlorophenyl)prop-2-enoyl]amino]-4,4-dimethylpentanamide Chemical compound CC(C)(C)C[C@@H](C(NC(C[C@H](CCN1)C1=O)C(C(NC1CC1)=O)=O)=O)NC(/C=C/C(C=CC(Cl)=C1)=C1Cl)=O BIIBYWQGRFWQKM-JVVROLKMSA-N 0.000 description 1
- BZHGTKWUWCLIAA-UHFFFAOYSA-N 1-[4-(2-chloroethyl)phenyl]-2-ethyl-4,6-dimethylimidazo[4,5-c]pyridine Chemical compound CCC1=NC2=C(C)N=C(C)C=C2N1C1=CC=C(CCCl)C=C1 BZHGTKWUWCLIAA-UHFFFAOYSA-N 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- DWKNOLCXIFYNFV-HSZRJFAPSA-N 2-[[(2r)-1-[1-[(4-chloro-3-methylphenyl)methyl]piperidin-4-yl]-5-oxopyrrolidine-2-carbonyl]amino]-n,n,6-trimethylpyridine-4-carboxamide Chemical compound CN(C)C(=O)C1=CC(C)=NC(NC(=O)[C@@H]2N(C(=O)CC2)C2CCN(CC=3C=C(C)C(Cl)=CC=3)CC2)=C1 DWKNOLCXIFYNFV-HSZRJFAPSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- PSBGFLWVQDGETK-UHFFFAOYSA-N 4-chloro-2,6-dimethyl-3-nitropyridine Chemical compound CC1=CC(Cl)=C([N+]([O-])=O)C(C)=N1 PSBGFLWVQDGETK-UHFFFAOYSA-N 0.000 description 1
- ALNJKHVWDMLOGI-UHFFFAOYSA-N C(C)C=1N(C2=C(C(=NC(=C2)C)C)N=1)C1=CC=C(C=C1)CCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)CC Chemical group C(C)C=1N(C2=C(C(=NC(=C2)C)C)N=1)C1=CC=C(C=C1)CCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)CC ALNJKHVWDMLOGI-UHFFFAOYSA-N 0.000 description 1
- SSFMPJKMONHGCH-UHFFFAOYSA-G CC1=CC(Cl)=C([N+](=O)[O-])C(C)=N1.CC1=CC(NC2=CC=C(CCO)C=C2)=C(N)C(C)=N1.CC1=CC(NC2=CC=C(CCO)C=C2)=C([N+](=O)[O-])C(C)=N1.CC1=CC=C(S(=O)(=O)OC#N)C=C1.CCC(=O)OCCC1=CC=C(N2C(CC)=NC3=C2C=C(C)N=C3C)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCCl)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCN)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCN=[N+]=[N-])C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCO)C=C1.CCOC(=O)NS(=O)(=O)C1=CC=C(C)C=C1.I.II.I[IH]I.I[V](I)I.I[V]I.NC1=CC=C(CCO)C=C1.[H]N(CCC1=CC=C(N2C(CC)=NC3=C2C=C(C)N=C3C)C=C1)C(=O)N([H])S(=O)(=O)C1=CC=C(C)C=C1.[V].[V]I.[V]I Chemical compound CC1=CC(Cl)=C([N+](=O)[O-])C(C)=N1.CC1=CC(NC2=CC=C(CCO)C=C2)=C(N)C(C)=N1.CC1=CC(NC2=CC=C(CCO)C=C2)=C([N+](=O)[O-])C(C)=N1.CC1=CC=C(S(=O)(=O)OC#N)C=C1.CCC(=O)OCCC1=CC=C(N2C(CC)=NC3=C2C=C(C)N=C3C)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCCl)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCN)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCN=[N+]=[N-])C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCO)C=C1.CCOC(=O)NS(=O)(=O)C1=CC=C(C)C=C1.I.II.I[IH]I.I[V](I)I.I[V]I.NC1=CC=C(CCO)C=C1.[H]N(CCC1=CC=C(N2C(CC)=NC3=C2C=C(C)N=C3C)C=C1)C(=O)N([H])S(=O)(=O)C1=CC=C(C)C=C1.[V].[V]I.[V]I SSFMPJKMONHGCH-UHFFFAOYSA-G 0.000 description 1
- UVBWFJQNGMBHKX-UHFFFAOYSA-O CC1=CC(NC2=CC=C(CCO)C=C2)=C([N+](=O)[O-])C(C)=N1.CCC1=NC2=C(C)[N+](O)=C(C)C=C2N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=CC=C(C)C=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=C(C)C=CC=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=CC(C)=CC=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNS(=O)(=O)C2=CC=C(C)C=C2)C=C1.Cl Chemical compound CC1=CC(NC2=CC=C(CCO)C=C2)=C([N+](=O)[O-])C(C)=N1.CCC1=NC2=C(C)[N+](O)=C(C)C=C2N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=CC=C(C)C=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=C(C)C=CC=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=CC(C)=CC=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNS(=O)(=O)C2=CC=C(C)C=C2)C=C1.Cl UVBWFJQNGMBHKX-UHFFFAOYSA-O 0.000 description 1
- HCNZEFKSXNMZCJ-UHFFFAOYSA-O CCC1=NC2=C(C)[N+](O)=C(C)C=C2N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=CC=C(C)C=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNC(=O)(=O)C2=CC=C(C)C=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=C(C)C=CC=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=CC(C)=CC=C2)C=C1 Chemical compound CCC1=NC2=C(C)[N+](O)=C(C)C=C2N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=CC=C(C)C=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNC(=O)(=O)C2=CC=C(C)C=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=C(C)C=CC=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=CC(C)=CC=C2)C=C1 HCNZEFKSXNMZCJ-UHFFFAOYSA-O 0.000 description 1
- NZHXRWKKXYGSDW-UHFFFAOYSA-O CCC1=NC2=C(C)[N+](O)=C(C)C=C2N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=CC=C(C)C=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=C(C)C=CC=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=CC(C)=CC=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNS(=O)(=O)C2=CC=C(C)C=C2)C=C1.CCCC1=CC=C(NC2=C([N+](=O)[O-])C(C)=NC(C)=C2)C=C1.Cl Chemical compound CCC1=NC2=C(C)[N+](O)=C(C)C=C2N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=CC=C(C)C=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=C(C)C=CC=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNC(=O)NS(=O)(=O)C2=CC(C)=CC=C2)C=C1.CCC1=NC2=C(C=C(C)N=C2C)N1C1=CC=C(CCNS(=O)(=O)C2=CC=C(C)C=C2)C=C1.CCCC1=CC=C(NC2=C([N+](=O)[O-])C(C)=NC(C)=C2)C=C1.Cl NZHXRWKKXYGSDW-UHFFFAOYSA-O 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- LQOGYPWAXXYKHV-UHFFFAOYSA-N Cl.CC1=NC(=CC(=C1[N+](=O)[O-])NC1=CC=C(C=C1)CCO)C Chemical compound Cl.CC1=NC(=CC(=C1[N+](=O)[O-])NC1=CC=C(C=C1)CCO)C LQOGYPWAXXYKHV-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 101150109738 Ptger4 gene Proteins 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VOVZXURTCKPRDQ-CQSZACIVSA-N n-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide Chemical compound C1[C@H](O)CCN1C1=NC=C(C(=O)NC=2C=CC(OC(F)(F)Cl)=CC=2)C=C1C1=CC=NN1 VOVZXURTCKPRDQ-CQSZACIVSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the invention relates to process for the preparation of grapiprant and its intermediates thereof.
- the invention also relates to grapiprant having a purity 98% or more and compounds of Formula (A), (B), (C) and (D) in an amount of 0.5 or less, relative to grapiprant, by area percentage of HPLC.
- the invention also relates to an amorphous form of grapiprant and process for preparation thereof.
- Grapiprant is a Non-COX inhibiting NSAID that specifically targets the EP4 receptor. It is indicated for the control of pain and inflammation associated with osteoarthritis in dogs. Its chemical name is 1-[2-(4- ⁇ 2-ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl ⁇ phenyl)ethyl]-3-(4-ethylphenyl)sulfonylurea. It has structural formula as represented by compound of Formula (I).
- U.S. Pat. No. 6,710,054 B2 discloses the compound of Formula (I) and various routes of synthesis for the preparation of aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents.
- U.S. Pat. No. 7,960,407 B2 discloses various crystalline forms of grapiprant which are designated as Form A and Form B.
- U.S. Pat. No. 9,265,756 B2 discloses other crystalline form of grapiprant which are designated as Form X, X 2 , X 3 , F, K, L, M and N.
- the object of the present invention is to provide a cost effective and commercially feasible process for the production of grapiprant.
- the present invention also discloses amorphous form of grapiprant and its amorphous solid dispersion.
- grapiprant having a purity 98% or more and compounds of Formula (A), (B). (C), and (D), in an amount of 0.5 or less, relative to grapiprant, by area percentage of HPLC:
- grapiprant having a purity 98% or more and the compounds of Formula (A), (B), (C), and (D), in an amount of 0.5 or less, relative to grapiprant, by area percentage of HPLC.
- an amorphous solid dispersion of grapiprant and a polymer in another general aspect, there is provided an amorphous solid dispersion of grapiprant and a polymer.
- an amorphous form of grapiprant in another general aspect, there is provided an amorphous form of grapiprant.
- a pharmaceutical composition comprising grapiprant and one or more of compounds of Formula (A), (B). (C), and (D).
- a pharmaceutical composition comprising grapiprant and one or more of compounds of Formula (A), (B), (C), and (D), wherein the grapiprant is having a purity of about 98% or more, and the compounds of Formula (A), (B), (C), and (D), are present in amount an amount of 0.5 or less, relative to grapiprant, by area percentage of HPLC.
- a pharmaceutical composition comprising grapiprant and one or more of compounds of Formula (A), (B), (C), and (D), wherein the grapiprant is having a purity of 98% or more, and the compounds of Formula (A), (B), (C), and (D), are present in an amount of 0.2 or less relative to grapiprant, by area percentage of HPLC.
- the grapiprant in the composition may be in amorphous form or in any crystalline or hydrated or anhydrous form.
- grapiprant having a purity of 95% or more, or 98% or more, or 99% or more, or 99.5% or more, or 99.8% or more, or 99.9% or more, by area percentage of HPLC.
- a pharmaceutical composition comprising amorphous solid dispersion of grapiprant and one or more of compounds of Formula (A), (B), (C), and (D), wherein the grapiprant is having a purity of about 98% or more, and one or more of compounds of Formula (A), (B), (C), and (D), in an amount an amount of 0.5% or less, relative to grapiprant, by area percentage of HPLC.
- grapiprant having particle size distributions wherein the 10th volume percentile particle size (D10) is 50 ⁇ m or less, the 50th volume percentile particle size (D50) is 200 ⁇ m or less, or the 90th volume percentile particle size (D90) is 400 ⁇ m or less, or any combination thereof.
- a pharmaceutical composition comprising an amorphous form or an amorphous solid dispersion of grapiprant and one or more of compounds of Formula (A), (B), (C), and (D), wherein the grapiprant is having a purity of 98% or more, and the compounds of Formula (A), (B), (C), and (D), in an amount of 0.5% or less, relative to grapiprant, by area percentage of HPLC, and a polymer together with one or more of pharmaceutically acceptable carriers, excipients or diluents.
- FIG. 1 X-ray diffractogram (XRD) of the amorphous grapiprant of Formula (I).
- isolation is generally interchangeable and include but not specifically limited to extraction, evaporation, crystallization, filtration, recrystallization or chromatographic operations.
- converting relates to reacting the compound, to which it refers, with another compound and/or reagent, and/or subjecting it to condition(s) such that it transforms to another compound as results of such process or treatment.
- the product(s) obtained may further be purified to obtain them in purer forms.
- the product(s) obtained may further be dried additionally to achieve desired level of moisture and/or residual solvents.
- the product(s) obtained may further be converted to any other physical forms thereof which includes but not specifically limited to salt(s), solvate(s), hydrate(s), co-crystal(s) and solid dispersion(s) in either crystalline or amorphous forms.
- solid dispersion means any solid composition having at least two components.
- a solid dispersion as disclosed herein includes an active ingredient grapiprant dispersed among at least one other component, for example a polymer.
- the product(s) obtained may further be subjected to physical processing which includes, but not limited to, pressing, crushing, triturating, milling or grinding to adjust the particle size of the product(s) to desired levels.
- Particle Size Distribution means the cumulative volume size distribution of equivalent spherical diameters as determined by laser diffraction in Malvern Master Sizer 2000 equipment or its equivalent.
- solution or “reaction mixture” does not limit to a clear solution only and includes any hazy or opaque mass obtained.
- composition means two or more substances present in combination, not in fixed proportions and not with chemical bonding.
- composition is intended to encompass a drug product including the active ingredient(s), pharmaceutically acceptable excipients that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients. Accordingly, the pharmaceutical compositions encompass any composition made by admixing the active ingredient, active ingredient dispersion or composite, additional active ingredient(s), and pharmaceutically acceptable excipients.
- grapiprant having a purity 98% or more, and compounds of Formula (A), (B), (C), and (D) in an amount of 0.5% or less, relative to grapiprant, by area percentage of HPLC,
- grapiprant having a purity 98% or more, and the compounds of Formula (A), (B), (C), and (D) in an amount of 0.5% or less, relative to grapiprant, by area percentage of HPLC.
- an amorphous solid dispersion of grapiprant and a polymer in another general aspect, there is provided an amorphous solid dispersion of grapiprant and a polymer.
- the solvent at the step (a) is selected from one or more of methanol, ethanol, isopropanol, 1-butanol, tert-butanol, acetonitrile, dichloromethane, acetone, cyclohexane, hexane, dimethyl formamide and dimethyl sulphoxide.
- the polymer at the step (b) may be a non-ionic polymer or an ionic polymer.
- the polymer comprises of hydroxypropyhmethyl cellulose acetate succinate (HPMC-AS), hydroxypropylmethyl cellulose (HPMC), methacrylic acid copolymers, polyvinyl pyrrolidone (PVP), and co-povidone.
- the removal of the solvents at the step (c) comprises one or more of distillation, distillation under vacuum, spray drying, agitated thin film dying (“ATFD”), and freeze drying (lyophilization).
- an amorphous solid dispersion of grapiprant and a polymer having a purity 98% or more and the compounds of Formula (A), (B), (C), and (D) in an amount of 0.5% or less, relative to grapiprant, by area percentage of HPLC.
- an amorphous form of grapiprant in another general aspect, there is provided an amorphous form of grapiprant.
- the solvent at step (a) is selected from one or more of C 1 -C 6 alcohols selected from methanol, ethanol, isopropanol, 1-butanol and tert-butanol; nitriles selected from acetonitrile and propionitrile; halogenated solvents selected from chloroform, ethylene dichloride, carbon tetrachloride, and dichloromethane; ketones selected from acetone; aliphatic hydrocarbons selected from cyclohexane and hexane; aromatic hydrocarbons selected from toluene and xylene; dimethyl sulphoxide; dimethyl formamide, ethers selected from THF and dioxane; and mixtures thereof.
- C 1 -C 6 alcohols selected from methanol, ethanol, isopropanol, 1-butanol and tert-butanol
- nitriles selected from acetonitrile and propionitrile
- halogenated solvents
- the removal of the solvents at step (b) comprises one or more of distillation, distillation under vacuum, spray drying, agitated thin film drying (“ATFD”), and freeze drying (lyophilization).
- reaction of the compound (II) and ethyl(p-tolylsulfonyl)carbamate may be performed in one or more solvents selected from ethyl acetate, isopropyl acetate, butyl acetate, benzene, toluene, xylene, methylene dichloride, ethylene dichloride, chloroform, and chlorobenzene.
- solvents selected from ethyl acetate, isopropyl acetate, butyl acetate, benzene, toluene, xylene, methylene dichloride, ethylene dichloride, chloroform, and chlorobenzene.
- toluene may be used.
- the base for the reaction can be selected from sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium carbonate, potassium carbonate lithium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydride, potassium tert-butoxide or triethyl amine, diisopropyl amine, diisopropylethylamine, pyridine, morpholine, piperidine, DBU or DABCO.
- triethyl amine can be used.
- the temperature range for the reaction may be selected from 50 to 100° C.
- the reaction is carried out at 80-85° C.
- reaction of 2-(4-aminophenyl)ethyl alcohol in step (a) of Formula (VIII) can be reacted with 4-chloro-2,6-dimethyl-3-nitropyridine compound of Formula (VII) in the presence of the polar aprotic solvents which may be selected from N-methyl pyrrolidone, dimethyl formamide and dimethyl sulfoxide.
- the reaction can be carried out in the presence of N-methyl-2-pyrrolidone at a temperature in the range of from about 50 to 120° C. Particularly, 75-110° C. to obtain a compound of Formula (VI).
- the compound of Formula (VI) at step (b) is treated with reducing reagent in one or more solvents to obtain a compound of Formula (V).
- the reaction can be performed at temperature range selected from 60-70° C. In particular, at 63-68° C.
- the reducing reagents for the reaction can be selected from Palladium/carbon, Raney Ni, ruthenium, rhodium and platinum and hydrazine hydrate, zinc metal in aqueous ammonium chloride, zinc metal with sodium hydroxide or using lithium aluminium hydride.
- Raney Ni and hydrazine hydrate can be used.
- the solvents for the reaction can be selected from methylene dichloride, ethylene dichloride, chloroform, chlorobenzene, N,N′-dimethyl formamide and dimethyl sulfoxide, C 1 -C 6 alcohols.
- methylene dichloride and methanol may be used.
- the compound of Formula (V) in step (c) is treated with propionic acid and propionic anhydride at temperature ranging from 80-150° C. Particularly, temperature ranging from 100-130° C.
- a base which may be selected from one or more of alkali metal carbonates selected from sodium carbonate, potassium carbonate and cesium carbonate; alkali metal bicarbonates selected from sodium bicarbonate and potassium bicarbonate; alkali metal hydroxides selected from sodium hydroxide, potassium hydroxide, magnesium hydroxide and lithium hydroxide; alkali metal hydride such as sodium hydride and potassium hydride.
- alkali metal carbonates selected from sodium carbonate, potassium carbonate and cesium carbonate
- alkali metal bicarbonates selected from sodium bicarbonate and potassium bicarbonate
- alkali metal hydroxides selected from sodium hydroxide, potassium hydroxide, magnesium hydroxide and lithium hydroxide
- alkali metal hydride such as sodium hydride and potassium hydride.
- Solvent for the reaction can be selected from one or more of water, C 1 -C 6 -alcohols selected from methanol, ethanol, isopropanol, 1-butanol and tert-butanol; nitriles selected from acetonitrile and propionitrile; halogenated solvents selected from chloroform, ethylene dichloride, carbon tetrachloride and dichloromethane; ketones selected from acetone; aliphatic hydrocarbons selected from cyclohexane and hexane; aromatic hydrocarbons selected from toluene and xylene; dimethyl sulphoxide; ethers selected from THF and dioxane; and mixtures thereof.
- water and methanol can be used.
- the compound of Formula (IV) in the step (d) is treated with thionyl chloride in presence of one or more solvents selected from methylene dichloride, ethylene dichloride, chloroform, chlorobenzene, N,N′-dimethylfomamide and dimethyl sulfoxide.
- solvents selected from methylene dichloride, ethylene dichloride, chloroform, chlorobenzene, N,N′-dimethylfomamide and dimethyl sulfoxide.
- methylene dichloride ethylene dichloride
- chloroform chlorobenzene
- N,N′-dimethylfomamide dimethyl sulfoxide
- dimethyl sulfoxide preferably, methylene dichloride.
- the chloro intermediate thus formed is treated with metal azide selected from sodium azide or potassium azide.
- metal azide selected from sodium azide or potassium azide.
- sodium azide solution in water is used to obtain the compound of Formula (III).
- reaction can be carried out in presence of polar aprotic solvent, which may be selected from dimethyl formamide, dimethyl sulfoxide, acetone, N-methyl pyrrolidine and acetonitrile.
- polar aprotic solvent which may be selected from dimethyl formamide, dimethyl sulfoxide, acetone, N-methyl pyrrolidine and acetonitrile.
- the compound of Formula (III) at step (e) can be reduced by a reducing agent selected from palladium/ammonium acetate, zinc/formic acid, zinc/acetic acid or by hydrogenation under 3-4 kg/cm 2 hydrogen pressure in the presence of catalyst and one or more solvents to obtain a compound of Formula (II).
- a reducing agent selected from palladium/ammonium acetate, zinc/formic acid, zinc/acetic acid or by hydrogenation under 3-4 kg/cm 2 hydrogen pressure in the presence of catalyst and one or more solvents to obtain a compound of Formula (II).
- the catalyst may be selected from Raney nickel, palladium/carbon, platinum, platinum dioxide. Particularly. Raney Nickel or Pd/C are used.
- Solvent for the reaction can be selected from water, C 1 -C 6 -alcohols for example methanol, ethanol, isopropanol, n-butanol, or mixture thereof.
- methanol can be used.
- step (f) the compound of Formula (II) in step (f) is reacted with ethyl(p-tolyl sulfonyl)carbamate or p-toluenesulfonyl isocyanate to obtain grapiprant.
- the reaction can be carried out in the presence of base in one or more solvents.
- the base for the reaction can be selected from sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium carbonate, potassium carbonate lithium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydride, potassium tert-butoxide or triethyl amine, diisopropyl amine, diisopropylethylamine, pyridine, morpholine, piperidine, DBU, or DABCO.
- triethyl amine can be used.
- the solvent for the reaction may be selected from one or more of C 1 -C 6 -alcohols selected from methanol, ethanol, isopropanol, 1-butanol and tert-butanol, nitriles selected from acetonitrile and propionitrile, halogenated solvents selected from methylene dichloride, ethylene dichloride, chloroform and chlorobenzene, carbon tetrachloride, aliphatic hydrocarbons selected from cyclohexane and hexane; aromatic hydrocarbons selected from benzene, toluene and xylene, dimethyl sulphoxide; ethers selected from THF and dioxane, esters selected from ethyl acetate, isopropyl acetate, butyl acetate.
- toluene or methylene dichloride may be used.
- the temperature range for the reaction may be selected from 50 to 100° C. In particular, the reaction is carried out at 80-85° C.
- a pharmaceutical composition comprising grapiprant and one or more of compounds of Formula (A), (B), (C), and (D):
- composition comprising grapiprant and one or more of compounds of Formula (A), (B), (C), and (D), wherein the grapiprant is having a purity of about 98% or more, and the compounds of Formula (A), (B), (C), and (D), are present in amount an amount of 0.5 or less, relative to grapiprant, by area percentage of HPLC.
- a pharmaceutical composition comprising grapiprant and one or more of compounds of Formula (A), (B), (C), and (D), wherein the grapiprant is having a purity of 98% or more, and the compounds of Formula (A), (B), (C), and (D) are present in an amount of 0.2% or less relative to grapiprant, by area percentage of HPLC.
- grapiprant having a purity of 95% or more, or 98% or more, or 99% or more, or 99.5% or more, or 99.8% or more, or 99.9% or more, by area percentage of HPLC.
- the grapiprant may be in amorphous form, crystalline form, hydrated from or in anhydrous form.
- grapiprant having particle size distributions wherein the 10th volume percentile particle size (D10) is 50 ⁇ m or less, the 50th volume percentile particle size (D50) is 200 ⁇ m or less, or the 90th volume percentile particle size (D90) is 400 ⁇ m or less, or any combination thereof.
- a pharmaceutical composition comprising an amorphous form or an amorphous solid dispersion of grapiprant and one or more of compounds of Formula (A), (B), (C), and (D), wherein the grapiprant is having a purity of 98% or more, and the compounds of Formula (A), (B), (C), and (D) are present in an amount of 0.5% or less relative to grapiprant, by area percentage of HPLC and a polymer together with one or more of pharmaceutically acceptable carriers, excipients or diluents.
- a pharmaceutical composition comprising amorphous grapiprant together with one or more pharmaceutically acceptable carriers, excipients or diluents.
- a pharmaceutical composition comprising an amorphous solid dispersion of grapiprant and a polymer together with one or more of pharmaceutically acceptable carriers, excipients or diluents.
- the layers were separated and the aqueous layer was taken in another flask and 55 mL ethyl acetate was added and stirred for 2-3 hours.
- the solid was filtered and washed with 11 mL water and 22 mL ethyl acetate.
- the solid was taken into another flask and 55 mL water and 55 mL MDC were added.
- a solution of 4 g sodium bicarbonate in 46 ml water was added into the reaction mixture at 25-35° C. to adjust pH to 7-7.5 and stirred for 15-30 minutes at 25-35° C.
- the layers were separated and the aqueous layer was washed with 22 mL MDC.
- the layers were separated and the aqueous layer was taken in another flask and 400 mL ethyl acetate was added and stirred for 2-3 hours.
- the solid was filtered and washed with 80 mL water and 160 ml ethyl acetate.
- the solid was taken into another flask and 400 mL water and 400 mL MDC were added.
- a solution of 30 g sodium bicarbonate in 345 mL water was added into the reaction mixture at 25-35° C. to adjust pH to 7-8 and stirred for 15-30 minutes at 25-35° C.
- the layers were separated and the aqueous layer was washed with 22 mL MDC.
- the organic layer was taken into another flask and the solvent was distilled out under vacuum.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This application is a Divisional of application Ser. No. 16/991,323 filed on Aug. 12, 2020, which claims priority from Indian Applications Nos. 201921032548 filed 12 Aug. 2019 and 202021014512 filed 1 Apr. 2020, the disclosures of which are incorporated in their entirety by reference herein.
- The invention relates to process for the preparation of grapiprant and its intermediates thereof. The invention also relates to grapiprant having a purity 98% or more and compounds of Formula (A), (B), (C) and (D) in an amount of 0.5 or less, relative to grapiprant, by area percentage of HPLC. The invention also relates to an amorphous form of grapiprant and process for preparation thereof.
- The following discussion of the prior art is intended to present the invention in an appropriate technical context and allow its significance to be properly appreciated. Unless clearly indicated to the contrary, however, reference to any prior art in this specification should be construed as an admission that such art is widely known or forms part of common general knowledge in the field.
- Grapiprant is a Non-COX inhibiting NSAID that specifically targets the EP4 receptor. It is indicated for the control of pain and inflammation associated with osteoarthritis in dogs. Its chemical name is 1-[2-(4-{2-ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl}phenyl)ethyl]-3-(4-ethylphenyl)sulfonylurea. It has structural formula as represented by compound of Formula (I).
- U.S. Pat. No. 6,710,054 B2 discloses the compound of Formula (I) and various routes of synthesis for the preparation of aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents.
- U.S. Pat. No. 7,960,407 B2 discloses various crystalline forms of grapiprant which are designated as Form A and Form B.
- U.S. Pat. No. 9,265,756 B2 discloses other crystalline form of grapiprant which are designated as Form X, X2, X3, F, K, L, M and N.
- The major drawback of the methods described in the prior art is that involves isolation by column chromatography or such techniques which are not a suitable for the scale up and commercial production and feasible only at laboratory scale. Therefore, the object of the present invention is to provide a cost effective and commercially feasible process for the production of grapiprant. The present invention also discloses amorphous form of grapiprant and its amorphous solid dispersion.
- In one general aspect, there is provided grapiprant having a purity 98% or more and compounds of Formula (A), (B). (C), and (D), in an amount of 0.5 or less, relative to grapiprant, by area percentage of HPLC:
- In another general aspect, there is provided grapiprant having a purity 98% or more and the compounds of Formula (A), (B), (C), and (D), in an amount of 0.5 or less, relative to grapiprant, by area percentage of HPLC.
- In another general aspect, there is provided an amorphous solid dispersion of grapiprant and a polymer.
- In another general aspect, there is provided an amorphous solid dispersion of grapiprant with a polymer having a purity 98% or more and the compounds of Formula (A), (B), (C), and (D), in an amount of 0.5 or less, relative to grapiprant, by area percentage of HPLC.
- In another general aspect, there is provided a compound of Formula (A), (B), (C), (D), and (VI):
- In another general aspect, there is provided an amorphous form of grapiprant.
- In another general aspect, there is provided a process for the preparation of amorphous grapiprant, the process comprising:
- (a) providing a solution of grapiprant in one or more solvents; and
- (b) obtaining the amorphous grapiprant by the removal of the solvent.
- In another general aspect, there is provided a process for the preparation of an amorphous solid dispersion of grapiprant and a polymer, the process comprising:
- (a) dissolving grapiprant in one or more solvent;
- (b) adding a polymer; and
- (c) removing the solvent to obtain the amorphous solid dispersion of grapiprant.
- In another general aspect, there is provided a process for the preparation of grapiprant comprising reacting a compound of Formula (II),
- with ethyl(p-tolylsulfonyl)carbamate.
- In another general aspect, there is provided a process for the preparation of grapiprant comprising reacting a compound of Formula (II),
- with ethyl(p-tolylsulfonyl)carbamate in the presence of a base.
- In another general aspect, there is provided a process for the preparation of the compound of Formula (II),
- the process comprising:
- (a) reacting a compound of Formula (VII) with a compound of Formula (VIII),
-
- to obtain a compound f Formula (VI):
- (b) converting the compound of Formula (VI) into a compound of Formula (V);
- (c) converting the compound of Formula (V) into a compound of Formula (IV):
- (d) converting the compound of Formula (IV) into a compound of Formula (III):
-
- and
- (e) converting the compound of Formula (III) into a compound of Formula (II).
- In another general aspect, there is provided a pharmaceutical composition comprising grapiprant and one or more of compounds of Formula (A), (B). (C), and (D).
- In another general aspect, there is provided a pharmaceutical composition comprising grapiprant and one or more of compounds of Formula (A), (B), (C), and (D), wherein the grapiprant is having a purity of about 98% or more, and the compounds of Formula (A), (B), (C), and (D), are present in amount an amount of 0.5 or less, relative to grapiprant, by area percentage of HPLC.
- In another general aspect, there is provided a pharmaceutical composition comprising grapiprant and one or more of compounds of Formula (A), (B), (C), and (D), wherein the grapiprant is having a purity of 98% or more, and the compounds of Formula (A), (B), (C), and (D), are present in an amount of 0.2 or less relative to grapiprant, by area percentage of HPLC.
- In general, the grapiprant in the composition may be in amorphous form or in any crystalline or hydrated or anhydrous form.
- In another general aspect, there is provided grapiprant having a purity of 95% or more, or 98% or more, or 99% or more, or 99.5% or more, or 99.8% or more, or 99.9% or more, by area percentage of HPLC.
- In another general aspect, there is provided a pharmaceutical composition comprising amorphous solid dispersion of grapiprant and one or more of compounds of Formula (A), (B), (C), and (D), wherein the grapiprant is having a purity of about 98% or more, and one or more of compounds of Formula (A), (B), (C), and (D), in an amount an amount of 0.5% or less, relative to grapiprant, by area percentage of HPLC.
- In another general aspect, there is provided grapiprant having particle size distributions wherein the 10th volume percentile particle size (D10) is 50 μm or less, the 50th volume percentile particle size (D50) is 200 μm or less, or the 90th volume percentile particle size (D90) is 400 μm or less, or any combination thereof.
- In another general aspect, there is provided a pharmaceutical composition comprising an amorphous form or an amorphous solid dispersion of grapiprant and one or more of compounds of Formula (A), (B), (C), and (D), wherein the grapiprant is having a purity of 98% or more, and the compounds of Formula (A), (B), (C), and (D), in an amount of 0.5% or less, relative to grapiprant, by area percentage of HPLC, and a polymer together with one or more of pharmaceutically acceptable carriers, excipients or diluents.
-
FIG. 1 : X-ray diffractogram (XRD) of the amorphous grapiprant of Formula (I). - The aforementioned general and further specific aspects of the invention are fulfilled by the description of the invention provided herein after.
- The terms ‘reacting’, ‘treating’ and ‘condensing’ are generally interchangeable and used in their ordinary meaning as they are in the field of the invention, unless otherwise specifically described.
- The terms ‘isolating’, ‘obtaining’ and ‘purifying’ are generally interchangeable and include but not specifically limited to extraction, evaporation, crystallization, filtration, recrystallization or chromatographic operations.
- The term ‘converting’ relates to reacting the compound, to which it refers, with another compound and/or reagent, and/or subjecting it to condition(s) such that it transforms to another compound as results of such process or treatment.
- The product(s) obtained may further be purified to obtain them in purer forms.
- The product(s) obtained may further be dried additionally to achieve desired level of moisture and/or residual solvents.
- The product(s) obtained may further be converted to any other physical forms thereof which includes but not specifically limited to salt(s), solvate(s), hydrate(s), co-crystal(s) and solid dispersion(s) in either crystalline or amorphous forms.
- As used herein, the term “solid dispersion” means any solid composition having at least two components. In certain embodiments, a solid dispersion as disclosed herein includes an active ingredient grapiprant dispersed among at least one other component, for example a polymer.
- The product(s) obtained may further be subjected to physical processing which includes, but not limited to, pressing, crushing, triturating, milling or grinding to adjust the particle size of the product(s) to desired levels.
- As used herein, “Particle Size Distribution (PSD)” means the cumulative volume size distribution of equivalent spherical diameters as determined by laser diffraction in Malvern Master Sizer 2000 equipment or its equivalent.
- As used herein, the term “solution” or “reaction mixture” does not limit to a clear solution only and includes any hazy or opaque mass obtained.
- The term “composition” means two or more substances present in combination, not in fixed proportions and not with chemical bonding.
- The term “pharmaceutical composition” is intended to encompass a drug product including the active ingredient(s), pharmaceutically acceptable excipients that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients. Accordingly, the pharmaceutical compositions encompass any composition made by admixing the active ingredient, active ingredient dispersion or composite, additional active ingredient(s), and pharmaceutically acceptable excipients.
- In one general aspect, there is provided grapiprant having a purity 98% or more, and compounds of Formula (A), (B), (C), and (D) in an amount of 0.5% or less, relative to grapiprant, by area percentage of HPLC,
- In another general aspect, there is provided grapiprant having a purity 98% or more, and the compounds of Formula (A), (B), (C), and (D) in an amount of 0.5% or less, relative to grapiprant, by area percentage of HPLC.
- In another general aspect, there is provided an amorphous solid dispersion of grapiprant and a polymer.
- In another general aspect, there is provided a process for the preparation of an amorphous solid dispersion of grapiprant with a polymer, comprising:
- (a) dissolving grapiprant in one or more solvent;
- (b) adding a polymer; and
- (c) removing the solvent to obtain the amorphous solid dispersion of grapiprant.
- In general, the solvent at the step (a) is selected from one or more of methanol, ethanol, isopropanol, 1-butanol, tert-butanol, acetonitrile, dichloromethane, acetone, cyclohexane, hexane, dimethyl formamide and dimethyl sulphoxide.
- In general, the polymer at the step (b) may be a non-ionic polymer or an ionic polymer. The polymer comprises of hydroxypropyhmethyl cellulose acetate succinate (HPMC-AS), hydroxypropylmethyl cellulose (HPMC), methacrylic acid copolymers, polyvinyl pyrrolidone (PVP), and co-povidone.
- In general, the removal of the solvents at the step (c) comprises one or more of distillation, distillation under vacuum, spray drying, agitated thin film dying (“ATFD”), and freeze drying (lyophilization).
- In another general aspect, there is provided an amorphous solid dispersion of grapiprant and a polymer having a purity 98% or more, and the compounds of Formula (A), (B), (C), and (D) in an amount of 0.5% or less, relative to grapiprant, by area percentage of HPLC.
- In another general aspect, there is provided a compound of Formula (A), (B), (C), (D), and (VI),
- In another general aspect, there is provided an amorphous form of grapiprant.
- In another general aspect, there is provided a process for the preparation of amorphous grapiprant, the process comprising:
- (a) providing a solution of grapiprant in one or more solvents; and
- (b) obtaining the amorphous grapiprant by the removal of the solvent.
- In general, the solvent at step (a) is selected from one or more of C1-C6 alcohols selected from methanol, ethanol, isopropanol, 1-butanol and tert-butanol; nitriles selected from acetonitrile and propionitrile; halogenated solvents selected from chloroform, ethylene dichloride, carbon tetrachloride, and dichloromethane; ketones selected from acetone; aliphatic hydrocarbons selected from cyclohexane and hexane; aromatic hydrocarbons selected from toluene and xylene; dimethyl sulphoxide; dimethyl formamide, ethers selected from THF and dioxane; and mixtures thereof.
- In general, the removal of the solvents at step (b) comprises one or more of distillation, distillation under vacuum, spray drying, agitated thin film drying (“ATFD”), and freeze drying (lyophilization).
- In another general aspect, there is provided a process for the preparation of grapiprant comprising reacting a compound of Formula (II),
- with ethyl(p-tolylsulfonyl)carbamate.
- In another general aspect, there is provided a process for the preparation of grapiprant comprising reacting a compound of Formula (II).
- with ethyl(p-tolylsulfonyl)carbamate in the presence of a base.
- In general, the reaction of the compound (II) and ethyl(p-tolylsulfonyl)carbamate may be performed in one or more solvents selected from ethyl acetate, isopropyl acetate, butyl acetate, benzene, toluene, xylene, methylene dichloride, ethylene dichloride, chloroform, and chlorobenzene. In particular, toluene may be used.
- In general, the base for the reaction can be selected from sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium carbonate, potassium carbonate lithium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydride, potassium tert-butoxide or triethyl amine, diisopropyl amine, diisopropylethylamine, pyridine, morpholine, piperidine, DBU or DABCO. In particular, triethyl amine can be used.
- In general, the temperature range for the reaction may be selected from 50 to 100° C. Preferably, the reaction is carried out at 80-85° C.
- In another general aspect, there is provided a process for preparation of grapiprant, the process comprising:
- (a) reacting a compound of Formula (VII) with a compound of Formula (VIII),
-
- to obtain a compound of Formula (VI);
- (b) converting the compound of Formula (VI) into a compound of Formula (V):
- (c) converting the compound of Formula (V) into a compound of Formula (IV):
- (d) converting the compound of Formula (IV) into a compound of Formula (III);
-
- and
- (e) converting the compound of Formula (III) into a compound of Formula (II).
- In general, the reaction of 2-(4-aminophenyl)ethyl alcohol in step (a) of Formula (VIII) can be reacted with 4-chloro-2,6-dimethyl-3-nitropyridine compound of Formula (VII) in the presence of the polar aprotic solvents which may be selected from N-methyl pyrrolidone, dimethyl formamide and dimethyl sulfoxide. Particularly, the reaction can be carried out in the presence of N-methyl-2-pyrrolidone at a temperature in the range of from about 50 to 120° C. Particularly, 75-110° C. to obtain a compound of Formula (VI).
- In general, the compound of Formula (VI) at step (b) is treated with reducing reagent in one or more solvents to obtain a compound of Formula (V). The reaction can be performed at temperature range selected from 60-70° C. In particular, at 63-68° C.
- In general, the reducing reagents for the reaction can be selected from Palladium/carbon, Raney Ni, ruthenium, rhodium and platinum and hydrazine hydrate, zinc metal in aqueous ammonium chloride, zinc metal with sodium hydroxide or using lithium aluminium hydride. In particular, Raney Ni and hydrazine hydrate can be used.
- In general, the solvents for the reaction can be selected from methylene dichloride, ethylene dichloride, chloroform, chlorobenzene, N,N′-dimethyl formamide and dimethyl sulfoxide, C1-C6 alcohols. In particular, methylene dichloride and methanol may be used.
- In general, the compound of Formula (V) in step (c) is treated with propionic acid and propionic anhydride at temperature ranging from 80-150° C. Particularly, temperature ranging from 100-130° C.
- It is then reacted with a base, which may be selected from one or more of alkali metal carbonates selected from sodium carbonate, potassium carbonate and cesium carbonate; alkali metal bicarbonates selected from sodium bicarbonate and potassium bicarbonate; alkali metal hydroxides selected from sodium hydroxide, potassium hydroxide, magnesium hydroxide and lithium hydroxide; alkali metal hydride such as sodium hydride and potassium hydride. Preferably using NaOH in presence of one or more solvents to obtain a compound of Formula (IV).
- Solvent for the reaction can be selected from one or more of water, C1-C6-alcohols selected from methanol, ethanol, isopropanol, 1-butanol and tert-butanol; nitriles selected from acetonitrile and propionitrile; halogenated solvents selected from chloroform, ethylene dichloride, carbon tetrachloride and dichloromethane; ketones selected from acetone; aliphatic hydrocarbons selected from cyclohexane and hexane; aromatic hydrocarbons selected from toluene and xylene; dimethyl sulphoxide; ethers selected from THF and dioxane; and mixtures thereof. In particular, water and methanol can be used.
- In general, the compound of Formula (IV) in the step (d) is treated with thionyl chloride in presence of one or more solvents selected from methylene dichloride, ethylene dichloride, chloroform, chlorobenzene, N,N′-dimethylfomamide and dimethyl sulfoxide. Preferably, methylene dichloride.
- The chloro intermediate thus formed is treated with metal azide selected from sodium azide or potassium azide. Preferably sodium azide solution in water is used to obtain the compound of Formula (III).
- In general, the reaction can be carried out in presence of polar aprotic solvent, which may be selected from dimethyl formamide, dimethyl sulfoxide, acetone, N-methyl pyrrolidine and acetonitrile.
- In general, the compound of Formula (III) at step (e) can be reduced by a reducing agent selected from palladium/ammonium acetate, zinc/formic acid, zinc/acetic acid or by hydrogenation under 3-4 kg/cm2 hydrogen pressure in the presence of catalyst and one or more solvents to obtain a compound of Formula (II).
- In general, the catalyst may be selected from Raney nickel, palladium/carbon, platinum, platinum dioxide. Particularly. Raney Nickel or Pd/C are used.
- In Solvent for the reaction can be selected from water, C1-C6-alcohols for example methanol, ethanol, isopropanol, n-butanol, or mixture thereof. In particular, methanol can be used.
- In general, the compound of Formula (II) in step (f) is reacted with ethyl(p-tolyl sulfonyl)carbamate or p-toluenesulfonyl isocyanate to obtain grapiprant.
- The reaction can be carried out in the presence of base in one or more solvents. In general, the base for the reaction can be selected from sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium carbonate, potassium carbonate lithium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydride, potassium tert-butoxide or triethyl amine, diisopropyl amine, diisopropylethylamine, pyridine, morpholine, piperidine, DBU, or DABCO. Particularly, triethyl amine can be used.
- In general, the solvent for the reaction may be selected from one or more of C1-C6-alcohols selected from methanol, ethanol, isopropanol, 1-butanol and tert-butanol, nitriles selected from acetonitrile and propionitrile, halogenated solvents selected from methylene dichloride, ethylene dichloride, chloroform and chlorobenzene, carbon tetrachloride, aliphatic hydrocarbons selected from cyclohexane and hexane; aromatic hydrocarbons selected from benzene, toluene and xylene, dimethyl sulphoxide; ethers selected from THF and dioxane, esters selected from ethyl acetate, isopropyl acetate, butyl acetate. In particular, toluene or methylene dichloride may be used.
- The temperature range for the reaction may be selected from 50 to 100° C. In particular, the reaction is carried out at 80-85° C.
- In another general aspect, there is provided a process for preparation of grapiprant as depicted in Scheme-I.
- In another general aspect, there is provided a pharmaceutical composition comprising grapiprant and one or more of compounds of Formula (A), (B), (C), and (D):
- In another general aspect, there is provided composition comprising grapiprant and one or more of compounds of Formula (A), (B), (C), and (D), wherein the grapiprant is having a purity of about 98% or more, and the compounds of Formula (A), (B), (C), and (D), are present in amount an amount of 0.5 or less, relative to grapiprant, by area percentage of HPLC.
- In another general aspect, there is provided a pharmaceutical composition comprising grapiprant and one or more of compounds of Formula (A), (B), (C), and (D), wherein the grapiprant is having a purity of 98% or more, and the compounds of Formula (A), (B), (C), and (D) are present in an amount of 0.2% or less relative to grapiprant, by area percentage of HPLC.
- In another general aspect, there is provided grapiprant having a purity of 95% or more, or 98% or more, or 99% or more, or 99.5% or more, or 99.8% or more, or 99.9% or more, by area percentage of HPLC.
- The grapiprant may be in amorphous form, crystalline form, hydrated from or in anhydrous form.
- In another general aspect, there is provided grapiprant having particle size distributions wherein the 10th volume percentile particle size (D10) is 50 μm or less, the 50th volume percentile particle size (D50) is 200 μm or less, or the 90th volume percentile particle size (D90) is 400 μm or less, or any combination thereof.
- In another general aspect, there is provided a pharmaceutical composition comprising an amorphous form or an amorphous solid dispersion of grapiprant and one or more of compounds of Formula (A), (B), (C), and (D), wherein the grapiprant is having a purity of 98% or more, and the compounds of Formula (A), (B), (C), and (D) are present in an amount of 0.5% or less relative to grapiprant, by area percentage of HPLC and a polymer together with one or more of pharmaceutically acceptable carriers, excipients or diluents.
- A pharmaceutical composition comprising amorphous grapiprant together with one or more pharmaceutically acceptable carriers, excipients or diluents.
- A pharmaceutical composition comprising an amorphous solid dispersion of grapiprant and a polymer together with one or more of pharmaceutically acceptable carriers, excipients or diluents.
- The examples are set forth to aid in understanding the invention but are not intended to, and should not be construed to limit its scope in any way. The examples do not include detailed descriptions of conventional methods. Such methods are well known to those of ordinary skill in the art and are described in various publications.
- In a 500 mL round bottom flask, a solution of compound of Formula (VII) (10 gm, 53.6 mmol) in N-methyl-2-pyrrolidone (17.5 ml) was heated to about 70-75° C. Another solution of compound of Formula (VIII) (7.0 gm 51.03 mmol) was prepared in N-methyl-2-pyrrolidone (10 ml) and added to the above reaction mass. Reaction was maintained at 80-100° C. for 2 hours. After completion of the reaction, it was cooled to the ambient temperature and ethyl acetate was added into the reaction mass. The reaction mass was stirred for an hour at ambient temperature and filtered and washed with ethyl acetate. The product was dried to obtain 2-(4-((2,6-dimethyl-3-nitropyridin-4-yl)amino)phenyl)ethan-1-ol hydrochloride i.e compound of Formula (VI)(15.5 gm, yield 94%).
- In 500 mL round bottom flask, a solution of compound of Formula (VI) (30 gm) in methanol (150 ml) was added. Raney Nickel (6 gm, 50% wet) was added and the reaction mass was heated to about 60-70° C. and hydrazine hydrate (80%, 29.1 gm) was added to the reaction mass dropwise. The reaction mass was then maintained at 60-70° C. for 2-4 hours. After completion of the reaction, the reaction mass was cooled to ambient temperature and catalyst was filtered on celite pad and washed with methanol. The solvent was then distilled off under vacuum to obtain a residue. The residue was then dissolved in methanol and then heated to about 50-55° C. and then ethyl acetate was added. The reaction mass was then cooled to 20-30° C. and stirred for one hour. The solids were then filtered and dried to obtain compound of Formula (V) (23.4 gm, yield 98.7%).
- In 500 mL round bottom flask, a mixture of propionic acid (42 ml) and propionic anhydride was added. Compound of Formula (V) (21 gm, 81.6 mmol) was then added to the above reaction mass and heated to about 110-120° C. The reaction mass was stirred for about 6-8 hours and then after completion of the reaction, the reaction mass was cooled to 25-35° C. 25% aqueous sodium hydroxide solution (185 gm) was added and then heated to 60-70° C. and maintained for 8 hours. After completion of reaction the reaction was cooled to ambient temperature and filtered and washed with water and dried to obtain compound of Formula (IV). (16.9 gm, yield 70%).
- In a 500 mL round bottom flask, a solution of compound of Formula (IV) (15 gm, 50.78 mmol) in dichloromethane (100 mL) was added and the reaction mass was cooled to 0-10° C. A solution of thionyl chloride (7.25 gm, 60.9 mmol) in dichloromethane was then added to the reaction mass at 0-10° C. The reaction mass was then maintained at 10-15° C. for 6 hours. After the completion of the reaction water was added to the reaction mass and (15 ml) and pH of the reaction mass was adjusted to 7-8 by using aqueous sodium carbonate solution. Layer were separated and the organic layer was then concentrated under reduced pressure to obtain 1-(4-(2-chloroethyl)phenyl)-2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridine (15.4 gm, yield 96.6%).
- The above residue was then dissolved in dimethyl formamide (30 mL). Potassium iodide (5.3 gm, 31.86 mmol) and sodium azide (3.1 gm, 47.8 mmol) were then added to the reaction mass and heated to 95-100° C. for 12 hours After completion of the reaction the reaction mass was cooled to ambient temperature. Water was added to the reaction mass to precipitate the product and stirred for 1 hour at ambient temperature. The product was then filtered and dried to obtain 1-(4-(2-azidoethyl)phenyl)-2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridine i.e. compound of Formula (III) (8.9 gm, yield 87%).
- In a 500 mL round bottom flask, a solution of compound of Formula (III) (1.77 gm, 5.52 mmol) in methanol (17.7 ml) and Raney Nickel (0.35 gm, 50% wet) were added. Reaction was then heated to about 65° C. and hydrazine hydrate (80%, 1.72 gm, 27.62 mmol) was added dropwise to the reaction mixture. The reaction mass was then maintained at 65-70° C. for 2 hours. After completion of the reaction the reaction mass was cooled to ambient temperature and catalyst was filtered. Solvent was distilled under vacuum to get the compound of Formula (II) (1.6 gm, yield 98.8%).
- In a 500 mL round bottom flask, a solution of compound of Formula (II) (4.5 g, 1.19 mmol) in dichloromethane (10 ml) was added. To the reaction mixture was then added 4-methylbenzenesulfonyl isocyanate (3 g, 1.31 mmol) at 25-35° C. The reaction mass was stirred for 4 hours. After completion of the reaction, solvent was evaporated to obtain a residue. Cyclohexane (45 ml) was added into the residue mass and heated to 65° C. to remove residual dichloromethane. The reaction mass was cooled to 25-35° C. and stirred for an hour. The product was filtered and washed with cyclohexane (13.5 ml). The product was dried at 55° C. for 6 hours to obtain the grapiprant of Formula (I) (7 gm).
- In 500 mL three necked round bottom flask, 20 g of grapiprant was dissolved in 200 mL of methanol at 25° C. to 50° C. The content was stirred for 30 minutes at 25° C. to 35° C. The solution was filtered through celite bed to get a clear solution of grapiprant. The clear solution was then spray dried by maintaining the inlet temperature in the range of 70° C. under nitrogen pressure of 5 kg/cm2 and maintaining the outlet temperature in the range of 50° C. The product was collected from cyclone and was further dried at 40° C.±5° C. under vacuum for 12 hours to get 17 g of amorphous grapiprant of Formula (I).
- In 500 mL three necked round bottom flask, 10 g of grapiprant and 100 mL methanol were added. The reaction was stirred for 30 minutes at 25-50° C. to get a clear solution. To the reaction mixture was then added 10 g of co-povidone and allowed to stir at 25-50° C. for 1 hour to get clear solution. The reaction mixture was then filtered through celite to get clear solution. The filtrate was then concentrated. The product was then dried at 50 to 60° C. to obtain 15.0 g amorphous solid dispersion of compound of Formula (I).
- In a round bottom flask, 40 mL N-methyl-2-pyrrolidone and 20 g of 2-(4-aminophenyl) ethyl alcohol were added and the reaction mixture was heated to 40-50° (C for 10-15 minutes to get a clear solution. In an another flask, 40 mL N-methyl-2-pyrrolidone and 28.57 g of 4-chloro-2,6-dimethyl-3-nitropyridine were added and the reaction mixture was stirred at 75-80° C. and the above solution of 2-(4-aminophenyl)ethyl alcohol was added into that within 30-60 minutes at 75-100° C. The reaction mixture was stirred at 80-100° C. for 2 hours. After completion of the reaction, the reaction mixture was cooled to 35-45° C. and 200 mL ethyl acetate was added within 20-40 minutes and stirred at 25-35° C. for an hour. The solid was filtered and washed with ethyl acetate and then dried at 65-70° C. under vacuum for 4 hours to obtain compound of Formula (VI). Yield: 95.34%, Purity: 99.85% w/w by HPLC.
- In a round bottom flask, 130 mL water and 40 g of compound of Formula (VI) were added and 50 mL water and 200 mL dichloromethane were added and stirred for 10-15 minutes, 5.2 g sodium hydroxide solution in 20 ml water was added into the reaction mixture at 25-35° C. and stirred for 15 minutes to adjust pH more than 10. The layers were separated and the organic layer was taken into another flask, washed with water and the solvent was distilled. 120 mL methanol and then a slurry of Raney Ni catalyst (8 g Raney Ni in 40 mL methanol) were added into the reaction mixture. The reaction mixture was heated to 63-68° C. 16.4 g of 80% hydrazine hydrate was added within 45-60 minutes and stirred for 2 hours at 63-68° C. After completion of the reaction, the reaction mixture was cooled and filtered. The filtrate was taken in another flask and methanol was distilled out and 240 mL water was added into the reaction mixture and stirred at 25-35° C. for 45-60 minutes and then the solid was filtered and washed with water and then dried at 50-55° C. under vacuum for 8 hours to obtain the compound of Formula (V). Yield: 94.39%, Purity: 97.17% w/w by HPLC.
- In a round bottom flask, 50 mL propionic acid and 25 g of compound of Formula (V) and 50 mL propionic anhydride were added and the reaction mixture was stirred at 110-120° C. for 6 hours. The reaction mixture was cooled to 25-35° C. and 50 mL water was added. 40% aqueous NaOH solution was added into the reaction mixture at 25-35° C. to adjust pH above 7 and then 125 mL ethyl acetate was added stirred for 30 minutes. The layers were separated and the organic layer was taken in another flask and the solvent was removed by distillation under vacuum and 50 mL methanol and 50 mL water were added 5.85 g NaOH was added into the reaction mixture and stirred till the completion of the reaction. 150 mL water was added stirred for 30-60 minutes at 25-35° C. The solid was filtered and washed with water and then dried at 70° C. for 6 hours to obtain the compound of Formula (IV). Yield: 76.02%, Purity: 98.95% w/w by HPLC.
- In a flask, 160 ml MDC, 20 g compound of Formula (IV) were taken and the reaction mixture was cooled to 15° C. a thionyl chloride solution (9.7 g thionyl chloride in 30 mL MDC) was added the reaction mixture was stirred at 25-35° C. for 3 hours. After completion of the reaction, it was cooled to 20-25° C. and 20 mL water was added and then 15% aq. sodium carbonate solution was added into the reaction mixture to adjust the pH between 6-8. The reaction mixture was stirred for 15 minutes and the layers were separated. The organic layer was taken in another flask and solvent was distilled. 100 mL DMF was added and the reaction mixture was heated to 50-70° C. and 6.6 g sodium azide solution in 40 mL water was added into the reaction mixture. The reaction mixture was stirred to 95-105° C. for 6 hours. After completion of the reaction, it was cooled to 25-35° C. and 280 mL water was added and stirred at 25-35° C. for around 2 hours. The solid was filtered and washed with water and then dried at 65° C. under vacuum for 6 hours to obtain the compound of Formula (II). Yield: 82.98%. Purity: 98.76% w/w by HPLC.
- In an autoclave, 75 mL methanol, 15 g compound of Formula (MH) and 3 g Raney nickel with 30 mL methanol were added under nitrogen atmosphere. The reaction mixture was stirred under 3-4 kg/cm2 hydrogen pressure at 40-45° C. After completion of the reaction, the reaction mass was cooled to 25-35° C. and filtered and washed with methanol. The filtrate was taken in another flask and the solvent was removed by distillation under vacuum below 60° C. 75 mL water and 75 mL MDC were added into the reaction mixture and pH was adjusted to 5.5 to 6.5 using conc. hydrochloric acid and stirred for 15 minutes. The layers were separated and the aqueous layer was taken in another flask and 75 mL MDC was added. pH was adjusted using 25% aqueous solution of NaOH and the reaction mixture was stirred. The layers were separated and the organic layer was taken in another flask and the solvent was distilled out to obtain a viscous oil. 3 mL MDC and 75 mL cyclohexane were added and the reaction mixture was stirred for 2 hours. The solid was filtered and washed with cyclohexane and then dried at 50-55° C. under vacuum for 6 hours to obtain the compound of Formula (I). Yield: 81.88%, Purity: 98.96% w/w by HPLC.
- In a flask, 300 mL acetone, 25 g p-toluene sulfonamide and 53.5 g powdered K2CO3 with 25 mL acetone were added. The reaction mixture was heated to 55-60° C. and stirred for 30 minutes. A solution of 21.07 g ethyl chloroformate in 50 mL acetone was added into the reaction mixture within 30-45 minutes and stirred at 55-60° C. for 2 hours. After completion of the reaction, the reaction mixture was cooled to 25-35° C. and 500 mL water was added and the pH of the reaction mass was adjusted to 3.5-4.5 using conc. HCl. 250 mL MDC was added into the reaction mixture and stirred for 30 minutes. The layers were settled and separated. The organic layer was taken in another flask and solvent was removed by distillation and 75 mL cyclohexane was added and stirred for one hour at 25-35° C. The solid was filtered and washed with cyclohexane and then dried at 50° C. under vacuum or 4 hours to obtain ETC.
- In a 500 mL, 4 neck round bottom flask, 100 mL toluene, 11 g compound of Formula (II), 7.56 g triethyl amine and 11 g ethyl (p-tolylsulfonyl) carbamate with 10 mL toluene were added. The reaction mixture was stirred at 80-90° C. for 4 hours. After completion of the reaction, the reaction mixture was cooled to 25-35° C. and 44 mL water was added and stirred for 15 minutes. The layers were separated and the aqueous layer was taken in another flask and 55 mL ethyl acetate was added and pH was adjusted to 1-3 using conc. hydrochloric acid and stirred for 15 minutes. The layers were separated and the aqueous layer was taken in another flask and 55 mL ethyl acetate was added and stirred for 2-3 hours. The solid was filtered and washed with 11 mL water and 22 mL ethyl acetate. The solid was taken into another flask and 55 mL water and 55 mL MDC were added. A solution of 4 g sodium bicarbonate in 46 ml water was added into the reaction mixture at 25-35° C. to adjust pH to 7-7.5 and stirred for 15-30 minutes at 25-35° C. The layers were separated and the aqueous layer was washed with 22 mL MDC. The organic layer was taken into another flask and the solvent was distilled out under vacuum and 77 mL cyclohexane was added. The reaction mixture was cooled to 25-35° C. and stirred for 30 minutes. The solid was filtered and washed with 22 mL cyclohexane and dried at 65-70° C. under vacuum for 6 hours to obtain grapiprant.
- In a 2 L, 4 neck round bottom flask, 720 mL toluene, 80 g compound of Formula (II), 55 g triethyl amine and 80 g ethyl (p-tolylsulfonyl)carbamate with 80 mL toluene were added and stirred at 80-90° C. for 4 hours. After completion of the reaction, the reaction mixture was cooled to 25-35° C. and 320 mL water was added and stirred for 15 minutes. The layers were separated and the aqueous layer was taken in another flask and 400 mL, ethyl acetate was added and pH was adjusted to 1-3 using conc. hydrochloric acid and stirred for 15-30 minutes. The layers were separated and the aqueous layer was taken in another flask and 400 mL ethyl acetate was added and stirred for 2-3 hours. The solid was filtered and washed with 80 mL water and 160 ml ethyl acetate. The solid was taken into another flask and 400 mL water and 400 mL MDC were added. A solution of 30 g sodium bicarbonate in 345 mL water was added into the reaction mixture at 25-35° C. to adjust pH to 7-8 and stirred for 15-30 minutes at 25-35° C. The layers were separated and the aqueous layer was washed with 22 mL MDC. The organic layer was taken into another flask and the solvent was distilled out under vacuum. After distillation, 640 mL acetone was added and the mixture was heated to 50-60° C. and acetone was distilled between 240 mL to 320 mL. The reaction mixture was stirred at 50-60° C. for 3-4 hours then cooled to 25-35° C. and stirred at this temperature for 90-120 minutes. The solid was filtered and washed with acetone and then dried to obtain grapiprant.
- In a Round bottom flask, 630 mL methanol and 70 g grapiprant were added and stirred at 25-35° C. to get a clear solution. This solution was fed into spray dryer using peristaltic pump at 10-12% pump speed and spray dried to obtain amorphous grapiprant.
-
-
B-290 Mini spray dryer with Inert loop Buchi Spray Dryer Model B-295 and Dehumidifier B-296 Inlet temperature set (° C.) 70-75 N2 pressure (Kg/cm2) 3-4 Aspirator-Blower RPM 65-85% Peristaltic pump RPM 10-12% - In a round bottom flask, 1 g N-((4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenethyl)carbamoyl)-4-methylbenzene sulfonamide was stirred with 10 mL chloroform at 25-35° C. 0.431 gm m-chloroperbenzoic acid was added and stirred at ambient temperature for 24 hours. After completion of the reaction, 10 mL water was added into that and stirred for 15-20 minutes and layers were separated. Organic layer concentrated under vacuum to get residue. Purification of the product was performed using silica gel (60-120 mesh) column chromatography and product eluted using 10% methanol/MDC followed by concentration to obtain the compound of Formula (D) i.e. N-oxide Grapiprant.
- While the present invention has been described in terms of its specific embodiments, certain modification and equivalents will be apartment to those skilled in the art and are intended to be included within the scope of the present invention.
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/383,978 US20210347776A1 (en) | 2019-08-12 | 2021-07-23 | Process for preparation of grapiprant |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201921032548 | 2019-08-12 | ||
IN201921032548 | 2019-08-12 | ||
IN202021014512 | 2020-04-01 | ||
IN202021014512 | 2020-04-01 | ||
US16/991,323 US11254675B2 (en) | 2019-08-12 | 2020-08-12 | Process for preparation of grapiprant |
US17/383,978 US20210347776A1 (en) | 2019-08-12 | 2021-07-23 | Process for preparation of grapiprant |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/991,323 Division US11254675B2 (en) | 2019-08-12 | 2020-08-12 | Process for preparation of grapiprant |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210347776A1 true US20210347776A1 (en) | 2021-11-11 |
Family
ID=74869347
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/991,323 Active US11254675B2 (en) | 2019-08-12 | 2020-08-12 | Process for preparation of grapiprant |
US17/383,978 Pending US20210347776A1 (en) | 2019-08-12 | 2021-07-23 | Process for preparation of grapiprant |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/991,323 Active US11254675B2 (en) | 2019-08-12 | 2020-08-12 | Process for preparation of grapiprant |
Country Status (1)
Country | Link |
---|---|
US (2) | US11254675B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116478155A (en) * | 2022-01-17 | 2023-07-25 | 洛阳惠中兽药有限公司 | Preparation method of grapiprant and intermediate thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004035522A (en) * | 2002-07-08 | 2004-02-05 | Sumitomo Chem Co Ltd | Method for producing n-methylurea compound |
WO2005092907A2 (en) * | 2004-03-26 | 2005-10-06 | Ranbaxy Laboratories Limited | Monosaccharide derivatives as anti-cancer and anti-inflammatory agents |
WO2005102389A2 (en) * | 2004-04-20 | 2005-11-03 | Pfizer Products Inc. | Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists |
US20150250774A1 (en) * | 2014-03-06 | 2015-09-10 | Aratana Therapeutics Inc. | Crystalline forms of grapiprant |
WO2020014445A1 (en) * | 2018-07-11 | 2020-01-16 | Arrys Therapeutics, Inc. | Ep4 inhibitors and synthesis thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HN2001000224A (en) | 2000-10-19 | 2002-06-13 | Pfizer | IMIDAZOL COMPOUNDS CONDENSED WITH ARILO OR HETEROARILO AS ANTI - INFLAMMATORY AND ANALGESIC AGENTS. |
KR100911073B1 (en) | 2005-03-11 | 2009-08-06 | 라퀄리아 파마 인코포레이티드 | Crystal forms of an imidazole derivative |
-
2020
- 2020-08-12 US US16/991,323 patent/US11254675B2/en active Active
-
2021
- 2021-07-23 US US17/383,978 patent/US20210347776A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004035522A (en) * | 2002-07-08 | 2004-02-05 | Sumitomo Chem Co Ltd | Method for producing n-methylurea compound |
WO2005092907A2 (en) * | 2004-03-26 | 2005-10-06 | Ranbaxy Laboratories Limited | Monosaccharide derivatives as anti-cancer and anti-inflammatory agents |
WO2005102389A2 (en) * | 2004-04-20 | 2005-11-03 | Pfizer Products Inc. | Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists |
US20150250774A1 (en) * | 2014-03-06 | 2015-09-10 | Aratana Therapeutics Inc. | Crystalline forms of grapiprant |
WO2020014445A1 (en) * | 2018-07-11 | 2020-01-16 | Arrys Therapeutics, Inc. | Ep4 inhibitors and synthesis thereof |
Non-Patent Citations (4)
Title |
---|
ANDO T., JP-2004035522-A. English Translation. (Year: 2004) * |
Marshall, F. J., et al. J. Med. Chem. 1963, 6, 1, 60–63. (Year: 1963) * |
Saczewski, F., et al. Green Chem., 2006, 8, 647–656. (Year: 2006) * |
Wang, J., et al. European Journal of Medicinal Chemistry. 76, 2014, 531-538. (Year: 2014) * |
Also Published As
Publication number | Publication date |
---|---|
US11254675B2 (en) | 2022-02-22 |
US20210079000A1 (en) | 2021-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11390583B2 (en) | Process for preparation of Siponimod, its salts and solid state forms thereof | |
US20160194301A1 (en) | Preparation of lenalidomide | |
ES2208265T3 (en) | TELMISARTAN POLYMORPHES, PROCEDURE FOR PREPARATION AND USE FOR THE PREPARATION OF A MEDICINAL PRODUCT. | |
US20210371397A1 (en) | Synthesis of omecamtiv mecarbil | |
WO2012090043A1 (en) | Novel solid state forms of azilsartan medoxomil and preparation thereof | |
US7064208B2 (en) | Substantially pure cilostazol and processes for making same | |
US20110014291A1 (en) | Novel Polymorphs of Bosentan | |
US20090054455A1 (en) | Aripiprazole co-crystals | |
US20210347776A1 (en) | Process for preparation of grapiprant | |
WO2018186365A1 (en) | Read-through inducing agent and pharmaceutical application thereof | |
US20070197535A1 (en) | Polymorphic forms of vardenafil | |
EP2093225A1 (en) | Process for preparing crystalline eletriptan hydrobromide form ß | |
WO2007103711A2 (en) | Polymorphic forms of rimonabant | |
US12060345B2 (en) | Process for preparing a phthalazinone derivative and intermediates thereof | |
US10301353B2 (en) | Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib | |
US7667037B2 (en) | Processes for preparation of ziprasidone | |
WO2018029699A1 (en) | Solid state forms of (2e)-n-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide and process for preparation thereof | |
US20120253051A1 (en) | Process for the preparation of ropinirole and salts thereof | |
WO2008017020A2 (en) | Process for preparing proton pump inhibitors | |
US20060004199A1 (en) | Process for the preparation of pure 3-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one | |
US7649008B2 (en) | Crystal of benzimidazole derivative and process for producing the same | |
US20100285075A1 (en) | Novel Hemioxalate Salt of Eletriptan | |
US8735408B2 (en) | Solid forms of 3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate | |
US20100087664A1 (en) | Preparation of citalopram and salts thereof | |
CN1242004A (en) | Process for making 2-amino-2-imidazoline, guanidine, and 2-amino-3,4,5,6-tetrahydropyrimidine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CADILA HEALTHCARE LIMITED, INDIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SINGH, KUMAR KAMLESH, DR.;GAJERA, JITENDRA MAGANBHAI, DR.;CHUNDAVAT, SUMER SINGH, DR.;AND OTHERS;REEL/FRAME:056963/0153 Effective date: 20200814 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
AS | Assignment |
Owner name: ZYDUS LIFESCIENCES LIMITED, INDIA Free format text: CHANGE OF NAME;ASSIGNOR:CADILA HEALTHCARE LIMITED;REEL/FRAME:068274/0823 Effective date: 20220224 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |